Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

BACKGROUND: Waning antibody levels post-vaccination and the emergence of variants of concern (VOCs) capable of evading protective immunity have raised the need for booster vaccinations. However, which combination of coronavirus disease 2019 (COVID-19) vaccines offers the strongest immune response ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Poh, Xuan Ying, Tan, Chee Wah, Lee, I Russel, Chavatte, Jean-Marc, Fong, Siew-Wai, Prince, Tessa, Hartley, Catherine, Yeoh, Aileen Y Y, Rao, Suma, Chia, Po Ying, Ong, Sean W X, Lee, Tau Hong, Sadarangani, Sapna P, Lin, Ray J H, Lim, Clarissa, Teo, Jefanie, Lim, Daniel R X, Chia, Wanni, Hiscox, Julian A, Ng, Lisa F P, Ren, Ee Chee, Lin, Raymond T P, Renia, Laurent, Lye, David Chien, Wang, Lin-Fa, Young, Barnaby E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129205/
https://www.ncbi.nlm.nih.gov/pubmed/35543372
http://dx.doi.org/10.1093/cid/ciac345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129205/
https://www.ncbi.nlm.nih.gov/pubmed/35543372
http://dx.doi.org/10.1093/cid/ciac345

Ejemplares similares